|
| Index | - | P/E | - | EPS (ttm) | -1.35 | Insider Own | 3.76% | Shs Outstand | 21.67M | Perf Week | 2.75% |
| Market Cap | 44.49M | Forward P/E | - | EPS next Y | -0.18 | Insider Trans | 0.00% | Shs Float | 19.94M | Perf Month | -3.03% |
| Income | -3.80M | PEG | - | EPS next Q | -0.04 | Inst Own | 23.80% | Short Float | 1.30% | Perf Quarter | -2.61% |
| Sales | - | P/S | - | EPS this Y | 41.80% | Inst Trans | 8.47% | Short Ratio | 0.56 | Perf Half Y | -11.11% |
| Book/sh | 4.22 | P/B | 0.53 | EPS next Y | 25.00% | ROA | -7.60% | Target Price | - | Perf Year | -84.60% |
| Cash/sh | 4.36 | P/C | 0.51 | EPS next 5Y | - | ROE | -7.70% | 52W Range | 1.79 - 21.00 | Perf YTD | -10.40% |
| Dividend | - | P/FCF | - | EPS past 5Y | 27.20% | ROI | - | 52W High | -89.33% | Beta | 0.02 |
| Dividend % | - | Quick Ratio | 141.60 | Sales past 5Y | - | Gross Margin | - | 52W Low | 25.14% | ATR | 0.12 |
| Employees | 4 | Current Ratio | 141.60 | Sales Q/Q | - | Oper. Margin | - | RSI (14) | 55.96 | Volatility | 5.14% 5.86% |
| Optionable | Yes | Debt/Eq | 0.00 | EPS Q/Q | 92.30% | Profit Margin | - | Rel Volume | 0.26 | Prev Close | 2.24 |
| Shortable | Yes | LT Debt/Eq | 0.00 | Earnings | - | Payout | - | Avg Volume | 462.33K | Price | 2.24 |
| Recom | 3.00 | SMA20 | 4.78% | SMA50 | 2.77% | SMA200 | -8.48% | Volume | 120,425 | Change | 0.00% |
 |
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| PharmaCyte Biotech, Inc., a biotechnology company, focuses on developing and commercializing cellular therapies for cancer and diabetes in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable non-metastatic pancreatic cancer, as well as diabetes. The company is developing therapies for pancreatic and other tumors, including encapsulated genetically modified living cells. It is also developing a therapy for Type 1 diabetes and insulin-dependent Type 2 diabetes; and therapies for cancer based on the constituents of the cannabis plant. The company has a research agreement with the University of Technology, Sydney to create a version of melligen cells to treat diabetes; and the University of Northern Colorado to develop methods for the identification, separation, and quantification of constituents of cannabis. The company was formerly known as Nuvilex, Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015. PharmaCyte Biotech, Inc. was incorporated in 1996 and is based in Laguna Hills, California. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
| open in yahoo | open in reuters | open in marketwatch | open in google |
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite